Among these, hyperactivation of the MAPK pathway is a hallmark of melanoma, primarily driven by mutations in critical signaling components such as B-Raf proto-oncogene, serine/threonine kinase (BRAF), NRAS proto-oncogene, GTPase (NRAS), neurofibromin 1(NF1), and KIT proto-oncogene, receptor tyrosine kinase (KIT) (4). This evidence concerns the gene NF1 and melanoma.